Auto Added by WPeMatico
Abbott and Google are linking continuous glucose monitoring data with Google’s AI-powered health coaching tools, giving the Gemini-powered service access to another source of personal health information. Under a multiyear agreement, data from Abbott’s Lingo continuous glucose monitor will be integrated into the Google Health app. Users will be able to view glucose trends alongside […]
Google AI health coach to use Abbott glucose data Read More »
Novo Nordisk is expanding its use of AWS artificial intelligence tools across drug discovery, including AI agents for target identification, therapy design, and research workflows. Under the agreement announced recently, AWS will become Novo Nordisk’s preferred cloud provider and strategic AI partner. The companies have also created a co-innovation hub at Novo Nordisk’s existing London
Novo Nordisk and AWS bring agentic AI into drug discovery Read More »
GSK has entered into a research collaboration with British biotechnology company Relation Therapeutics worth up to $110 million, expanding the companies’ existing work in AI-assisted drug discovery. Under the agreement, Relation will generate large-scale datasets measuring how human cells respond to genetic changes and drug interventions. The data will be used to train AI models
Why biological data matters more in AI drug discovery Read More »
Insilico Medicine has reduced the time needed to produce some drug development candidates to about one year by combining artificial intelligence with laboratory research in China, according to CEO Alex Zhavoronkov. The Hong Kong-listed company’s fastest programme reached candidate nomination in nine months, while its typical timeline is about 13 months, Zhavoronkov said. He said
How AI is shortening drug discovery timelines in China Read More »
Bristol Myers Squibb is purchasing an Nvidia DGX SuperPOD built on the chipmaker’s Vera Rubin architecture to support artificial intelligence use across its drug discovery and development operations. The pharmaceutical company said it will be the first life sciences group to acquire a DGX SuperPOD based on Vera Rubin. Nvidia introduced the architecture earlier this
Bristol Myers Squibb buys Nvidia AI system for drug discovery Read More »
Public health departments across the United States will test generative AI tools under a new programme involving the Coalition for Health AI, OpenAI, Anthropic, and Accenture. The Public Health Use Case and Learning Scaling Engine, known as PULSE, will support trials in 10 state, local, tribal, or territorial jurisdictions. The programme is intended to produce
US public health agencies to test OpenAI and Anthropic AI models Read More »
Several NHS hospitals are preparing to use an AI-powered blood test to help assess women referred for possible womb cancer before invasive checks are carried out. According to The Guardian, around 90,000 postmenopausal women in England are referred by GPs each year for checks after experiencing heavy bleeding. About 10,000 women are diagnosed with womb
NHS AI blood test could reduce invasive womb cancer checks Read More »
Building AI systems in healthcare isn’t just a technical challenge. It’s a regulatory one. In most industries, data pipelines focus on: Scalability Performance Cost In US healthcare, everything revolves around: Compliance Privacy Traceability If your AI pipeline mishandles patient data, it’s not just a bug, it’s a legal risk. This is where ADLC (AI-driven software
AI Data Pipelines for US Healthcare: HIPAA, PHI Handling and Audit Logs Explained Read More »
OpenAI is introducing sandbox execution that allows enterprise governance teams to deploy automated workflows with controlled risk. Teams taking systems from prototype to production have faced difficult architectural compromises regarding where their operations occurred. Using model-agnostic frameworks offered initial flexibility but failed to fully utilise the capabilities of frontier models. Model-provider SDKs remained closer to
OpenAI Agents SDK improves governance with sandbox execution Read More »
The Health Insurance Portability and Accountability Act (HIPAA) sets the standard for protecting patient data in healthcare. A crucial aspect of this is de-identifying Protected Health Information (PHI). De-identification removes personal identifiers from health data for patient privacy. Among the methods available, HIPAA Expert Determination stands out. This method balances data utility with privacy, a
HIPAA Expert Determination for De-Identification Read More »
